This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Imperial College Innovations Limited, Myricx Pharma Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 173 
1 out of 2 Years Active: 2026
Title: Roger Bonnert: Innovator in Cytotoxic Compounds
Introduction
Roger Bonnert is a notable inventor based in Cointrin, Geneva, Switzerland. He has made significant contributions to the field of therapeutic compounds, particularly through his innovative work on cytotoxic imidazo[1,2-a]pyridine compounds.
Latest Patents
Bonnert holds a patent for "Cytotoxic Imidazo[1,2-A]Pyridine Compounds and Their Use in Therapy." This patent represents his commitment to advancing medical therapies and improving treatment options for various conditions. He has 1 patent to his name.
Career Highlights
Throughout his career, Roger Bonnert has worked with esteemed organizations such as Myricx Pharma Limited and Imperial College Innovations Limited. His experience in these companies has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.
Collaborations
Bonnert has collaborated with notable professionals in his field, including Robin Carr and Roberto Solari. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Roger Bonnert's work in the field of cytotoxic compounds showcases his dedication to innovation and therapeutic advancements. His contributions continue to impact the medical community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile